Emerging evidence suggests that the breast cancer transcriptome has a wide range of intratumoral heterogeneity, as well as genomic heterogeneity based on ER, PR, and Her2, which are determined by the tumor cells and immune cells in the surrounding microenvironment (Chung et al., 2017). This evidence concerns the gene ERBB2 and neoplasm.